t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia

Bone Marrow Transplant. 1997 Jun;19(12):1255-8. doi: 10.1038/sj.bmt.1700811.

Abstract

A 40-year-old male with Ph-positive CML underwent PBSC autografting after initial treatment with hydroxyurea and interferon. Following autograft he remained in chronic phase with cytogenetic or molecular evidence of low levels of residual Ph-positive cells. However, additional cytogenetic abnormalities, including t(3;21) typically seen in therapy-related myelodysplastic syndrome (MDS) and AML and blast crisis of CML, developed as an independent cell line following the autograft. More than 4 years after the autograft, the patient remains in chronic phase with no evidence of accelerated phase or blast crisis of CML, but with a concurrent MDS. We report a case of CML who developed therapy-related MDS following PBSC autograft while still remaining in chronic phase.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Chromosome Banding
  • Chromosomes, Human, Pair 21*
  • Chromosomes, Human, Pair 3*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Hydroxyurea / therapeutic use
  • Interferons / therapeutic use
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukemia, Myeloid, Chronic-Phase / drug therapy
  • Leukemia, Myeloid, Chronic-Phase / genetics*
  • Leukemia, Myeloid, Chronic-Phase / therapy*
  • Male
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / genetics
  • Time Factors
  • Translocation, Genetic*
  • Transplantation, Autologous

Substances

  • Antineoplastic Agents
  • Interferons
  • Hydroxyurea